Pharmaceuticals

Global Next Generation Antibody Drug Market Analysis 2025–2029: Opportunities for Strategic Growth

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Next Generation Antibody Drug Market Expected To Become By 2029 Compared With Its 2025 Level?

Recent years have seen a rapid expansion in the size of the next generation antibody drug market. Its valuation is set to increase from $14.26 billion in 2024 to $16.4 billion in 2025, progressing at a compound annual growth rate (CAGR) of 15.0%. The expansion witnessed in the historical timeframe is attributable to a growing demand for targeted therapies, the rising incidence of cancer, the increasing adoption of immuno-oncology therapies, a heightened focus on autoimmune diseases, and strengthened regulatory support.

The next generation antibody drug market size is anticipated to experience rapid expansion in the coming years. It is projected to grow to $29.08 billion in 2029, with a compound annual growth rate (CAGR) of 15.4%. This growth over the forecast period is attributable to increasing demand for personalized medicine, expanding drug pipelines, rising healthcare awareness, growing research collaborations, and an increasing aging population. Significant trends for the forecast period include advancements in antibody-drug conjugates, technological developments in bispecific antibodies, the integration of next-generation sequencing, progress in protein engineering, and enhanced integration of gene therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

What Are The Top Growth Drivers Impacting The Next Generation Antibody Drug Market Outlook?

An escalating emphasis on personalized medicine is anticipated to stimulate expansion within the next-generation antibody-drug market moving ahead. This medical methodology involves customizing treatment and healthcare plans for individual patients, considering their genetic makeup, environmental influences, and lifestyle choices, thereby providing more effective and precisely targeted therapeutic solutions. The growth of personalized medicine is fueled by innovations in genomic sequencing, facilitating more accurate diagnoses and specific treatment approaches. Next-generation antibody drugs contribute to the heightened focus on personalized medicine by enabling the creation of targeted therapies specifically adapted to patients’ unique genetic profiles and disease attributes, thereby enhancing effectiveness and reducing side effects. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based entity advocating for personalized medicine, revealed that the United States Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare disease patients in 2023, an increase from 6 approvals in 2022. Consequently, the heightened attention on personalized medicine is a key driver for the next-generation antibody drug market.

What Are The Segment Types Shaping The Next Generation Antibody Drug Market?

The next generation antibody drug market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies

3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration, Oral Formulations, Transdermal Delivery Systems

4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications

5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies

3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

Which Competitive Trends Are Defining The Next Generation Antibody Drug Market Structure?

Leading companies in the next generation antibody drug market are concentrating on creating novel solutions, notably antibody-drug conjugates, to advance targeted cancer treatments, boost therapeutic effectiveness, and lessen systemic toxicity. An antibody-drug conjugate (ADC) represents a focused cancer therapy, uniting a monoclonal antibody and a cytotoxic drug through a linker to specifically deliver the medication to tumor cells, thereby mitigating harm to healthy tissue. As an illustration, in January 2024, BioNTech SE, a biotechnology firm based in Germany, collaborated with Duality Biologics (Suzhou) Co. Ltd., a pharmaceutical company from China. This partnership led to their next-generation antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, which targets platinum-resistant ovarian cancer, receiving Fast Track designation from the U.S. Food and Drug Administration (FDA). This drug leverages DualityBio’s inventive DITAC (Duality Immune Toxin Antibody Conjugates) platform, which integrates a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery of the treatment directly to cancer cells. The capacity of BNT325/DB-1305 to accurately target cancer cells while limiting harm to healthy tissues is a significant benefit, improving treatment efficacy and diminishing adverse effects.

Who Are The Major Companies Operating In The Next Generation Antibody Drug Market?

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

How Do Regional Market Performances Compare Within The Next Generation Antibody Drug Industry?

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in the next generation antibody drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Next Generation Antibody Drug Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24335&type=smp

Browse Through More Reports Similar to the Global Next Generation Antibody Drug Market 2025, By The Business Research Company

Next Generation Personalized Beauty Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-personalized-beauty-global-market-report

Next Generation Personalized Beauty Market 2025

https://www.thebusinessresearchcompany.com/report/next-generation-personalized-beauty-market

Next Generation Firewall Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795